DiaCarta Introduces QFusion™ Single-Tube qPCR Assay for ALK Fusion Gene Detection

by | Sep 26, 2016 | Press Releases

DiaCarta today announced the introduction of QFusion™ RT-qPCR assay, a new product for the comprehensive, rapid and reliable detection of ALK fusion gene variants. The assay enables users to detect ten EML4-ALK and three KIF5B-ALK fusion gene variants in a single tube of multiplexed reactions with only 50 ng of RNA from FFPE samples in approximately 1.5 hours. It addresses critical issues in fluorescence in situ hybridization (FISH), the “gold standard” technique in fusion gene analysis, by eliminating objective interpretations of chromosomal break-apart patterns and reducing turnaround time by more than ten-fold.

Joining QClamp® EGFR and KRAS gene mutation detection kits in the DiaCarta’s lung cancer panel, the QFusion™ assay provides researchers and pathologists with a new tool to expand and accelerate their research in non-small cell lung cancer (NSCLC). The assay is the only commercial qPCR kit on the market that detects both EML4-ALK and KIF5B-ALK fusion gene variants, covering 95% of EML4-ALK and 90% KIF5B-ALK variants found in the COSMIC database for NSCLC. QFusion™ ALK generates highly specific results and accurately detects as low as 50 fusion templates in each reaction.

“I am excited about the launch of our QFusion™ ALK fusion gene detection assay. It is a best in class product that provides comprehensive, rapid and robust detection of not only the widely studied EML4-ALK but also the novel KIF5B-ALK fusion genes. Our one-tube assay is an alternative to the laborious slide-based ALK fusion gene assays, especially FISH, and it is designed to improve the quality and productivity of NSCLC research in many labs where real-time PCR machines are routinely used,” said Michael Powell, Ph.D., Chief Scientific Officer of DiaCarta. “As an innovator in precision molecular diagnostics, DiaCarta is uniquely positioned to deliver advanced solutions for cancer research and diagnostic applications. Among a suite of tests that we are planning to launch within the next year, QFusionTM ALK is one of them, and it has been designed and developed in our CLIA- and ISO 13485-certified facility.”

About DiaCarta, Inc.

Headquartered in Richmond, California with an ISO 13485-certified facility, DiaCarta develops, manufactures and markets cancer research and IVD products for precision molecular diagnostics. We specialize in genomic testing for biomarkers and offer clinical sample testing services in our CLIA-certified lab. We have also established our business operations and clinical service lab in Shanghai and Nanjing, China, respectively. QClamp® and OptiSeq™ are xeno nucleic acid (XNA) based technologies that enable highly sensitive detection of actionable mutations using qPCR and next-generation sequencing (NGS) platforms, respectively, for liquid biopsy and other traditionally challenging specimens. Other XNA applications include CRISPR/Cas9 gene-editing event screening and adapter dimer removal for NGS library preparation. To learn more, visit https://www.diacarta.com.

Lead Source

DiaCarta Expands Board Leadership with Industry Veteran

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.

DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!